These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30548704)

  • 1. Volumetric
    Chotchutipan T; Rosen BS; Hawkins PG; Lee JY; Saripalli AL; Thakkar D; Eisbruch A; El Naqa I; Mierzwa ML
    Head Neck; 2019 Feb; 41(2):366-373. PubMed ID: 30548704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
    Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
    J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pretreatment ¹⁸F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma.
    Cheng NM; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Liao CT; Lin CY; Hsu CL; Yen TC
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1673-84. PubMed ID: 22854984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
    Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
    Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging.
    Floberg JM; DeWees TA; Chin RI; Garsa AA; Dehdashti F; Nussenbaum B; Oppelt PJ; Adkins DR; Gay HA; Thorstad WL
    Head Neck; 2018 Oct; 40(10):2280-2287. PubMed ID: 30051553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anal cancer chemoradiotherapy outcome prediction using
    Rusten E; Rekstad BL; Undseth C; Klotz D; Hernes E; Guren MG; Malinen E
    Br J Radiol; 2019 May; 92(1097):20181006. PubMed ID: 30810343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
    Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
    Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy.
    Liu HY; Milne R; Lock G; Panizza BJ; Bernard A; Foote M; McGrath M; Brown E; Gandhi M; Porceddu SV
    Oral Oncol; 2019 Jan; 88():153-159. PubMed ID: 30616786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
    Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
    Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy.
    Kim KH; Lee J; Chang JS; Lee CG; Yun M; Choi EC; Kim SH; Keum KC
    Head Neck; 2016 Oct; 38(10):1515-24. PubMed ID: 27062085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-treatment Fluorodeoxyglucose Positron Emission Tomography in Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma Treated with Primary Radiotherapy: Nodal Metabolic Response Rate can Predict Treatment Outcomes.
    Lin P; Min M; Lai K; Lee M; Holloway L; Xuan W; Bray V; Fowler A; Lee CS; Yong J
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e586-e598. PubMed ID: 34373179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus-Positive Versus Human Papillomavirus-Negative Patients With Oropharyngeal Cancer.
    Gouw ZAR; La Fontaine MD; van Kranen S; van de Kamer JB; Vogel WV; van Werkhoven E; Sonke JJ; Al-Mamgani A
    Clin Nucl Med; 2019 May; 44(5):e323-e328. PubMed ID: 30889002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Hawkins PG; Mierzwa ML; Bellile E; Jackson WC; Malloy KM; Chinn SB; Spector ME; Shuman AG; Stucken CL; McLean SA; Bradford CR; Prince ME; Carey TE; Worden FP; Swiecicki PL; Taylor JMG; Wolf GT; Eisbruch A; Casper KA
    Head Neck; 2019 Apr; 41(4):857-864. PubMed ID: 30775826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma.
    Taghipour M; Marcus C; Califano J; Fakhry C; Subramaniam RM
    J Med Imaging Radiat Oncol; 2015 Dec; 59(6):681-6. PubMed ID: 26768092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.